Industry Articles
A Deep Dive into EMBALL'ISO: A strategic global expansion
| Update : 9th October, 2025 |
By EMBALL'ISO
A leading company in transformation
For over 35 years, EMBALL'ISO has supported pharmaceutical laboratories, clinical trial operators, logistics providers, and last-mile specialists in managing and reducing risks related to the cold chain. This expertise, built over more than three decades, has earned the company a reputation for reliability in a sector where even the smallest failure can compromise the effectiveness of medicines.
As a global leader in the design and manufacturing of high-performance insulated packaging solutions for pharmaceutical transport, EMBALL'ISO has also become a recognized expert in Reuse & Reverse Logistics. This expertise reflects the company’s strategic evolution, demonstrating its ability to anticipate environmental challenges while maintaining the highest standards of quality and safety.
An exceptional global network
With 12 production sites across 4 continents including France, Germany, the United Kingdom, the United States, Mexico, Brazil, China, India, Japan, Singapore, and Vietnam and more than 15 service centers and recovery partners in over 80 countries, EMBALL'ISO has built a unique system enabling the reuse of insulated packaging. The company employs over 220 people worldwide.
This strategic global presence allows EMBALL'ISO to meet the specific needs of each region while optimizing transportation costs and delivery times. As a result, clients can save valuable time, achieve significant cost reductions, and greatly reduce their environmental footprint. Three goals that are perfectly aligned with the current challenges facing the pharmaceutical industry.
Excellence through continuous innovation
All EMBALL’ISO products are designed, tested, and validated by an in-house R&D team composed of specialized engineers and technicians, supported by a design office at the forefront of innovation. These teams continuously work on improving thermal performance and enhancing the durability of the solutions provided. Internal testing laboratories, certified to the international standards, ensure that every innovation is validated before being launched on the market.
The solutions developed deliver outstanding thermal stability from -80°C to +37°C through the use of refrigerant gels and phase change materials (PCMs). This wide temperature range meets the full spectrum of pharmaceutical industry needs from ultra-sensitive vaccines to gene therapies, as well as traditional medicines and medical devices.
EMBALL’ISO’s passive isothermal packaging solutions address every requirement, from the secure transport of a single vial to large-capacity containers for air freight. Their modularity ensures a perfect fit with each customer’s specific demands.
A comprehensive and tailored range of services
To help its clients optimize the cold chain, EMBALL’ISO has developed a full suite of turnkey services that goes beyond the simple supply of packaging. These services include “ready-to-use” solutions for immediate implementation, as well as sophisticated Reuse and Reverse logistics programs designed to maximize reusability.
Modernization and expansion of headquarters
EMBALL’ISO’s French headquarters is currently undergoing major expansion and modernization works, scheduled for completion by the end of the year 2025. This investment will provide the capacity to accommodate the company’s continuously growing teams.
The company has already recruited new talent in key strategic departments. The Laboratory Study Department, the true heart of EMBALL’ISO’s innovation, has welcomed new specialized engineers and technicians. These reinforcements will accelerate the development of ever more efficient solutions and ensure anticipation of regulatory developments within the industry.
The production team has also been strengthened to meet rising demand and to prepare for the integration of new production capacities currently being deployed internationally. These new team members bring valuable expertise in industrial automation, quality control, and manufacturing process optimization. Overall, the factory’s surface area in France has increased by 50%.
New production plant in Brazil
EMBALL’ISO’s international expansion is taking a new step forward with the construction of a new production plant in Brazil, scheduled to open next November. This strategic investment reflects the company’s confidence in the potential of the South American market and its commitment to strengthening proximity with local customers.
With its strategic geographic location and rapidly growing pharmaceutical market, Brazil represents a natural gateway to the entire South American continent.
Strengthening presence in Asia
In parallel with its South American expansion, EMBALL’ISO is consolidating its footprint in the Asian market through the installation of dedicated units within a third-party logistics (3PL) warehouse in South Korea. This strategic initiative, following the official opening of the Korean subsidiary in 2024, perfectly illustrates EMBALL’ISO’s pragmatic and flexible approach to entering new markets.
This partnership-based approach with 3PL operators is fully aligned with EMBALL’ISO’s global regional distribution strategy, enabling flexibility and rapid adaptation to local market developments. It also allows the company to focus on its core business, the design and production of high-performance isothermal packaging while leveraging the recognized logistics expertise of local partners.
Reuse & Reverse Logistics: A Major Competitive Advantage
One of EMBALL’ISO’s most innovative and differentiating features is its Reuse & Reverse Logistics service, which fully manages the return logistics of its clients’ packaging. This approach transforms what has traditionally been seen as a logistical constraint into a genuine competitive advantage.
EMBALL’ISO retrieves its isothermal packaging in more than 80 countries across four continents, a logistical feat made possible by its global network of partners and service centers. This exceptional geographic coverage ensures all clients, regardless of location, receive consistent high-quality service and optimized return timelines.
The reuse & reverse logistics process developed by EMBALL’ISO is guided by a clear philosophy: “save time and money while reducing environmental impact.” This triple value proposition perfectly addresses the current concerns of the pharmaceutical industry, which must balance operational performance, cost control, and environmental responsibility.
An optimized & environmentally friendly process
The EMBALL’ISO Reuse and Reverse service manages the collection of reusable packaging at its final destination. These packages are returned via the mode of transport with the lowest carbon footprint to the nearest EMBALL’ISO service center. This proactive environmental approach is part of a committed and measurable sustainable development strategy.
Once collected, the packaging undergoes a rigorous refurbishment process: cleaning according to strict protocols, replacement of worn components, and quality controls that ensure performance equivalent to that of new packaging. This focus on quality allows EMBALL’ISO to offer reused solutions that provide the same level of performance and safety as new products.
The system’s flexibility enables optimized reuse: packaging can be redeployed within the same country to meet new needs or shipped by sea freight to other regions based on global demand. This worldwide resource pooling provides significant economic and environmental benefits.
Three key benefits for clients
- Leverage EMBALL’ISO’s expertise and network: Clients gain immediate access to over 35 years of cold chain management experience and an international logistics network.
- Significantly reduce costs.
- Greatly improve environmental footprint: Systematic reuse of packaging, optimized return transport, and pooled logistics flows contribute to a drastic reduction in environmental impact, in line with pharmaceutical companies’ sustainable development goals.
A story of continuous innovation
The story of EMBALL’ISO, founded by Pierre Casoli, current CEO and Chemical Engineer, perfectly illustrates the ability of a French company to conquer international markets through innovation and operational excellence. Specializing in the design and production of isothermal packaging for the medical and pharmaceutical sectors, the company has continuously evolved and adapted to the challenges of its time.
Timeline of a successful expansion
- 1990: Pierre Casoli, Chemical Engineer, establishes EMBALL’ISO, specializing in the design and production of isothermal packaging for the medical and pharmaceutical sectors.
- Internationalization begins: The company establishes a subsidiary in Germany. 2004 marks a dual strategic expansion with new subsidiaries in the United Kingdom (EMBALL’ISO-M2 Ltd) and China. Singapore joins the network in 2005, consolidating EMBALL’ISO’s presence in Asia. The ISO9001 certification obtained by EMBALL’ISO France the same year, later extended to all subsidiaries, harmonizes quality standards internationally.
- 2009: Investment in a new headquarters, equipped with a geothermal heat pump, reflects EMBALL’ISO’s early commitment to environmental responsibility. The facility addresses three objectives: supporting client growth, optimizing production, and complying with the strictest safety and environmental standards.
- Intercontinental Expansion: The U.S. subsidiary established in 2014 positions EMBALL’ISO on the world’s largest pharmaceutical market. In 2015, the company pursues global ambitions with simultaneous expansions in India and Brazil, anticipating growth in emerging markets.
- 2021–2024: Opening of service centers in Canada, Ireland, and Switzerland (2021), a production site in Mexico (2022) and Vietnam (2024), and subsidiaries in Australia and South Korea (2024) completes 35 years of continuous expansion.
This trajectory demonstrates how EMBALL’ISO has consistently developed and innovated, strengthening its global leadership in pharmaceutical isothermal packaging year after year. Today, present on four continents with 12 production sites and over 15 service centers, the company continues its growth momentum with current projects including headquarters expansion, the upcoming launch of a new, higher-capacity facility in Brazil to complement its existing operations, and the reinforcement of its Asian presence highlighting its ongoing ability to adapt to the evolving global market.
About EMBALL'ISO
EMBALL’ISO plays a significant role in managing cold chain risks, providing solutions such as rental services, reverse logistics, and connected solutions that help pharmaceutical labs, clinical trial operators, and logistics companies control the temperature of their products from production to delivery. Within 35 years, EMBALL’ISO has expanded to four continents with 12 factories (Brazil, China, France, Germany, India, Japan, Mexico, Singapore, Vietnam, the UK, and the US), more than 15 service hubs allowing both a global supply and –more importantly – the introduction of reuse networks for insulated packaging on an international level. For more information visit emballiso.com
Discover our rapidly growing pharma cold chain community
Follow us on LinkedIn for expert interviews, industry news, and insights from the pharma cold chain world.
Follow us on LinkedIn
EMBALL'ISO News
BIX 2026 to Explore Pharma Cold Chain Strategies from Clinical Development to Global Commercialization
Interview with Bob McClain, Regional Head of Sales, North America at EMBALL’ISO: Scaling Reuse and Resilience in Pharma Cold Chain
